These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134 [TBL] [Abstract][Full Text] [Related]
26. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. Cavaletti G; Jann S; Pace A; Plasmati R; Siciliano G; Briani C; Cocito D; Padua L; Ghiglione E; Manicone M; Giussani G; J Peripher Nerv Syst; 2006 Jun; 11(2):135-41. PubMed ID: 16787511 [TBL] [Abstract][Full Text] [Related]
27. [Chemotherapy-induced peripheral neuropathy; impact on quality of life]. Scheel A; Beijers AJ; Mols F; Faber CG; Vreugdenhil G Ned Tijdschr Geneeskd; 2014; 158():A7455. PubMed ID: 25315326 [TBL] [Abstract][Full Text] [Related]
28. Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity. Alberti P; Bernasconi DP; Cornblath DR; Merkies ISJ; Park SB; Velasco R; Bruna J; Psimaras D; Koeppen S; Pace A; Dorsey SG; Argyriou AA; Kalofonos HP; Briani C; Schenone A; Faber CG; Mazzeo A; Grisold W; Valsecchi M; Cavaletti G; Neurology; 2021 Aug; 97(7):e660-e672. PubMed ID: 34078718 [TBL] [Abstract][Full Text] [Related]
29. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206 [TBL] [Abstract][Full Text] [Related]
30. Pronociceptive Roles of Schwann Cell-Derived Galectin-3 in Taxane-Induced Peripheral Neuropathy. Koyanagi M; Imai S; Matsumoto M; Iguma Y; Kawaguchi-Sakita N; Kotake T; Iwamitsu Y; Ntogwa M; Hiraiwa R; Nagayasu K; Saigo M; Ogihara T; Yonezawa A; Omura T; Nakagawa S; Nakagawa T; Matsubara K Cancer Res; 2021 Apr; 81(8):2207-2219. PubMed ID: 33608316 [TBL] [Abstract][Full Text] [Related]
31. Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy. McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Friedlander M; Bosco A; Harrison M; Maier N; O'Neill S; Park SB J Pain Symptom Manage; 2019 Dec; 58(6):1023-1032. PubMed ID: 31374367 [TBL] [Abstract][Full Text] [Related]
32. Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients. Mahfouz FM; Park SB; Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; King T; Goldstein D; Mizrahi D Clin Auton Res; 2022 Dec; 32(6):497-506. PubMed ID: 36129622 [TBL] [Abstract][Full Text] [Related]
33. Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors. Knoerl R; Mazzola E; Mitchell SA; Hong F; Salehi E; McCleary N; Ligibel JA; Reyes K; Berry DL J Patient Rep Outcomes; 2021 Sep; 5(1):101. PubMed ID: 34568984 [TBL] [Abstract][Full Text] [Related]
34. Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy. Kautio AL; Haanpää M; Kautiainen H; Leminen A; Kalso E; Saarto T Anticancer Res; 2011 Oct; 31(10):3493-6. PubMed ID: 21965767 [TBL] [Abstract][Full Text] [Related]
35. Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer. Lee KM; Jung D; Hwang H; Son KL; Kim TY; Im SA; Lee KH; Hahm BJ J Psychosom Res; 2018 May; 108():14-19. PubMed ID: 29602320 [TBL] [Abstract][Full Text] [Related]
36. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice. Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460 [TBL] [Abstract][Full Text] [Related]
37. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741 [TBL] [Abstract][Full Text] [Related]
39. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling. Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099 [TBL] [Abstract][Full Text] [Related]
40. Study Protocol for Assessing the Efficacy of Compression Therapy Using Stockings and Sleeves to Prevent Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients. Yamanouchi K; Kuba S; Matsumoto M; Yano H; Morita M; Sakimura C; Otsubo R; Kanetaka K; Nagayasu T; Eguchi S Acta Med Okayama; 2020 Oct; 74(5):455-459. PubMed ID: 33106704 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]